1. PI3K/mTOR dual-inhibition with VS-5584 enhances anti-leukemic efficacy of ponatinib in blasts and Ph-negative LSCs of chronic myeloid leukemia
   Cagla Kayabasi et al, 2021, European Journal of Pharmacology CrossRef
2. Bad phosphorylation as a target of inhibition in oncology
   Ngoc-Linh-Chi Bui et al, 2018, Cancer Letters CrossRef
3. Molecular cloning of the Bombus terrestris bumblebee venom protein phospholipase A 2 and its anti-leukemia effects on K562 cells
   Yuling Qiu et al, 2017, Journal of Asia-Pacific Entomology CrossRef
4. Atorvastatin Exerts Antileukemia Activity via Inhibiting Mevalonate-YAP Axis in K562 and HL60 Cells
   Lei Zhang et al, 2019, Frontiers in Oncology CrossRef
5. EP4 receptor agonist L-902688 augments cytotoxic activities of ibrutinib, idelalisib, and venetoclax against chronic lymphocytic leukemia cells
   Sanja Nabergoj et al, 2021, Biochemical Pharmacology CrossRef
6. Synergistic Effects of PI3K Inhibition on Arsenic Trioxide Cytotoxicity in Acute Promyelocytic Leukemia Cells: A New Portrait of Idelalisib as an Adjuvant Therapy
   Maryam Dadashi et al, 2023, Indian Journal of Hematology and Blood Transfusion CrossRef
7. Idelalisib
   Katja Zirlik et al, 2018, Small Molecules in Hematology CrossRef
8. RETRACTED ARTICLE: Idelalisib promotes Bim-dependent apoptosis through AKT/FoxO3a in hepatocellular carcinoma
   Dan Yue et al, 2018, Cell Death & Disease CrossRef